Pharma BD Deal Intelligence

AbbVie Inc. / Stemcentrx Inc.

2012 · Acquisition/Merger · $5.8B · Complete

Announcement Sentiment

25

Negative

Outcome Score

16

Did not work — the deal failed to deliver.

AbbVie acquired Stemcentrx for up to $9.8B to enhance oncology pipeline.

Key facts

Announced Nov 17, 2012
Closed May 30, 2016
Deal value $5.8B
Deal type Acquisition/Merger
Therapeutic area Oncology

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals